COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
Considerable data indicate posttransplant lenalidomide prolongs progression-free survival and probably survival after an autotransplant for plasma cell myeloma (PCM). However, optimal therapy duration is unknown, controversial and differs in the EU and US. We compared outcomes and cost-effectiven...
Main Authors: | Monia Marchetti, Robert Peter Gale, Giovanni Barosi |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2021-04-01
|
Series: | Mediterranean Journal of Hematology and Infectious Diseases |
Subjects: | |
Online Access: | https://www.mjhid.org/index.php/mjhid/article/view/4555 |
Similar Items
-
COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
by: Monia Marchetti, et al.
Published: (2021-04-01) -
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2014-08-01) -
POOR HEMOPOIETIC STEM CELL MOBILIZERS IN MULTIPLE MYELOMA : A SINGLE INSTITUTION EXPERIENCE
by: Aura Ramirez-Medina, et al.
Published: (2010-05-01) -
POOR HEMOPOIETIC STEM CELL MOBILIZERS IN MULTIPLE MYELOMA : A SINGLE INSTITUTION EXPERIENCE
by: Guillermo Jose Ruiz-Delgado, et al.
Published: (2010-06-01) -
Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
by: Susana Aceituno, et al.
Published: (2018-06-01)